301. Bradley TD, Hall MJ, Ando S, et al. Hemodynamic effects of simulated obstructive apneas in humans with and without heart failure. Chest 2001; 119:
1827-1835.
302. Shiomi T, Guilleminault C, Stoohs R, et al. Leftward shift of the interventricular septum and pulsus paradoxus in obstructive sleep apnea syndrome.
Chest 1991; 100: 894-902.
303. Shamsuzzaman AS, Gersh BJ, Somers VK. Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA 2003; 290: 1906-1914.
304. Solin P, Bergin P, Richardson M, et al. Influence of pulmonary capillary wedge pressure on central apnea in heart failure. Circulation 1999; 99: 1574-
1579.
305. Tkacova R, Hall MJ, Liu PP, et al. Left ventricular volume in patients with heart failure and Cheyne-Stokes respiration during sleep. Am J Respir Crit
Care Med 1997; 156: 1549-1555.
306. Solin P, Kaye DM, Little PJ, et al. Impact of sleep apnea on sympathetic nervous system activity in heart failure. Chest 2003; 123: 1119-1126.
307. Spaak J, Egri ZJ, Kubo T, et al. Muscle sympathetic nerve activity during wakefulness in heart failure patients with and without sleep apnea.
Hypertension 2005; 46: 1327-1332.
308. Arzt M, Harth M, Luchner A, et al. Enhanced ventilatory response to exercise in patients with chronic heart failure and central sleep apnea. Circulation
2003; 107: 1998-2003.
309. Javaheri S. A mechanism of central sleep apnea in patients with heart failure. N Eng J Med 1999; 341: 949-954.
310. Wilcox I, McNamara SG, Dodd MJ, et al. Ventilatory control in patients with sleep apnoea and left ventricular dysfunction: comparison of obstructive
and central sleep apnoea. Eur Respir J 1998; 11: 7-13.
311. Marin JM, Carrizo SJ, Vicente E, et al. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment
with continuous positive airway pressure: an observational study. Lancet 2005; 365: 1046-1053.
312. Buchner NJ, Sanner BM, Borgel J, et al. Continuous positive airway pressure treatment of mild to moderate obstructive sleep apnea reduces
cardiovascular risk. Am J Respir Crit Care Med 2007; 176: 1274-1280.
313. Roebuck T, Solin P, Kaye DM, et al. Increased long-term mortality in heart failure due to sleep apnoea is not yet proven. Eur Respir J 2004; 23: 735-740.
314. Wang H, Parker JD, Newton GE, et al. Influence of obstructive sleep apnea on mortality in patients with heart failure. J Am Coll Cardiol 2007; 49: 1625-
1631.
315. Lanfranchi PA, Braghiroli A, Bosimini E, et al. Prognostic value of nocturnal Cheyne-Stokes respiration in chronic heart failure. Circulation 1999; 99:
1435-1440.
316. Sin DD, Logan AG, Fitzgerald FS, et al. Effects of continuous positive airway pressure on cardiovascular outcomes in heart failure patients with and
without Cheyne-Stokes respiration. Circulation 2000; 102: 61-66.
317. Javaheri S, Shukla R, Zeigler H, et al. Central sleep apnea, right ventricular dysfunction, and low diastolic blood pressure are predictors of mortality in
systolic heart failure. J Am Coll Cardiol 2007; 49: 2028-2034.
318. Corra U, Pistono M, Mezzani A, et al. Sleep and exertional periodic breathing in chronic heart failure: prognostic importance and interdependence.
Circulation 2006; 113: 44-50.
319. Hanly PJ, Zuberi-Khokhar NS. Increased mortality associated with Cheyne-Stokes respiration in patients with congestive heart failure. Am J Respir Crit
Care Med 1996; 153: 272-276.
320. Tamura A, Kawano Y, Kadota J. Carvedilol reduces the severity of central sleep apnea in chronic heart failure. Circ J 2009; 73: 295-298.
321. Javaheri S. Acetazolamide improves central sleep apnea in heart failure: a double-blind, prospective study. Am J Respir Crit Care Med 2006; 173: 234-
237.
322. Sinha AM, Skobel EC, Breithardt OA, et al. Cardiac resynchronization therapy improves central sleep apnea and Cheyne-Stokes respiration in patients
with chronic heart failure. J Am Coll Cardiol 2004; 44: 68-71.
323. Gabor JY, Newman DA, Barnard-Roberts V, et al. Improvement in Cheyne-Stokes respiration following cardiac resynchronisation therapy. Eur Respir J
2005; 26: 95-100.
324. Oldenburg O, Faber L, Vogt J, et al. Influence of cardiac resynchronisation therapy on different types of sleep disordered breathing. Eur J Heart Fail 2007;
9: 820-826.
325. Bucca CB, Brussino L, Battisti A, et al. Diuretics in obstructive sleep apnea with diastolic heart failure. Chest 2007; 132: 440-446.
326. Walsh JT, Andrews R, Starling R, et al. Effects of captopril and oxygen on sleep apnoea in patients with mild to moderate congestive cardiac failure. British
heart journal 1995; 73: 237-241.
327. Tamura A, Kawano Y, Naono S, et al. Relationship between beta-blocker treatment and the severity of central sleep apnea in chronic heart failure. Chest
2007; 131: 130-135.
328. Kara T, Novak M, Nykodym J, et al. Short-term effects of cardiac resynchronization therapy on sleep-disordered breathing in patients with systolic heart
failure. Chest 2008; 134: 87-93.
329. Somers VK, Dyken ME, Clary MP, et al. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest 1995; 96: 1897-1904.
330. Narkiewicz K, Pesek CA, van de Borne PJ, et al. Enhanced sympathetic and ventilatory responses to central chemoreflex activation in heart failure.
Circulation 1999; 100: 262-267.
331. Kaneko Y, Floras JS, Usui K, et al. Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea.
N Eng J Med 2003; 348: 1233-1241.
332. Mansfield DR, Gollogly NC, Kaye DM, et al. Controlled trial of continuous positive airway pressure in obstructive sleep apnea and heart failure. Am J Respir
Crit Care Med 2004; 169: 361-366.
333. Usui K, Bradley TD, Spaak J, et al. Inhibition of awake sympathetic nerve activity of heart failure patients with obstructive sleep apnea by nocturnal
continuous positive airway pressure. J Am Coll Cardiol 2005; 45: 2008-2011.
334. Tkacova R, Dajani HR, Rankin F, et al. Continuous positive airway pressure improves nocturnal baroreflex sensitivity of patients with heart failure and
obstructive sleep apnea. Journal of hypertension 2000; 18: 1257-1262.
335. Ryan CM, Usui K, Floras JS, et al. Effect of continuous positive airway pressure on ventricular ectopy in heart failure patients with obstructive sleep
apnoea. Thorax 2005; 60: 781-785.
336. Arias MA, Garcia-Rio F, Alonso-Fernandez A, et al. Obstructive sleep apnea syndrome affects left ventricular diastolic function: effects of nasal
continuous positive airway pressure in men. Circulation 2005; 112: 375-383.
337. Smith LA, Vennelle M, Gardner RS, et al. Auto-titrating continuous positive airway pressure therapy in patients with chronic heart failure and obstructive
sleep apnoea: a randomized placebo-controlled trial. Eur Heart J 2007; 28: 1221-1227.
338. Kasai T, Narui K, Dohi T, et al. Prognosis of patients with heart failure and obstructive sleep apnea treated with continuous positive airway pressure. Chest
2008; 133: 690-696.
339. Meurice JC, Paquereau J, Denjean A, et al. Influence of correction of flow limitation on continuous positive airway pressure efficiency in sleep
apnoea/hypopnoea syndrome. Eur Respir J 1998; 11: 1121-1127.
340. Ferguson KA, Ono T, Lowe AA, et al. A randomized crossover study of an oral appliance vs nasal-continuous positive airway pressure in the treatment of
mild-moderate obstructive sleep apnea. Chest 1996; 109: 1269-1275.
341. Naughton MT, Liu PP, Bernard DC, et al. Treatment of congestive heart failure and Cheyne-Stokes respiration during sleep by continuous positive airway
pressure. Am J Respir Crit Care Med 1995; 151: 92-97.
342. Naughton MT, Benard DC, Liu PP, et al. Effects of nasal CPAP on sympathetic activity in patients with heart failure and central sleep apnea. Am J Respir
Crit Care Med 1995; 152: 473-479.
343. Tkacova R, Liu PP, Naughton MT, et al. Effect of continuous positive airway pressure on mitral regurgitant fraction and atrial natriuretic peptide in
patients with heart failure. J Am Coll Cardiol 1997; 30: 739-745.
344. Javaheri S. Effects of continuous positive airway pressure on sleep apnea and ventricular irritability in patients with heart failure. Circulation 2000; 101:
392-397.
345. Bradley TD, Logan AG, Kimoff RJ, et al. Continuous positive airway pressure for central sleep apnea and heart failure. N Eng J Med 2005; 353: 2025-2033.
346. Arzt M, Floras JS, Logan AG, et al. Suppression of central sleep apnea by continuous positive airway pressure and transplant-free survival in heart failure:
a post hoc analysis of the Canadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failure Trial (CANPAP).
Circulation 2007; 115: 3173-3180.
347. Dohi T, Kasai T, Narui K, et al. Bi-level positive airway pressure ventilation for treating heart failure with central sleep apnea that is unresponsive to
continuous positive airway pressure. Circ J 2008; 72: 1100-1105.
348. Noda A, Izawa H, Asano H, et al. Beneficial effect of bilevel positive airway pressure on left ventricular function in ambulatory patients with idiopathic
dilated cardiomyopathy and central sleep apnea-hypopnea: a preliminary study. Chest 2007; 131: 1694-1701.
349. Johnson KG, Johnson DC. Bilevel positive airway pressure worsens central apneas during sleep. Chest 2005; 128: 2141-2150.
350. Teschler H, Dohring J, Wang YM, et al. Adaptive pressure support servo-ventilation: a novel treatment for Cheyne- Stokes respiration in heart failure.
Am J Respir Crit Care Med 2001; 164: 614-619.
351. Pepperell JC, Maskell NA, Jones DR, et al. A randomized controlled trial of adaptive ventilation for Cheyne-Stokes breathing in heart failure. Am J Respir
Crit Care Med 2003; 168: 1109-1114.
352. Philippe C, Stoica-Herman M, Drouot X, et al. Compliance with and effectiveness of adaptive servoventilation versus continuous positive airway pressure
in the treatment of Cheyne-Stokes respiration in heart failure over a six month period. Heart (British Cardiac Society) 2006; 92: 337-342.
353. Kasai T, Narui K, Dohi T, et al. First experience of using new adaptive servo-ventilation device for Cheyne-Stokes respiration with central sleep apnea
among Japanese patients with congestive heart failure: report of 4 clinical cases. Circ J 2006; 70: 1148-1154.
354. Kasai T, Usui Y, Yoshioka T, et al. Effect of flow-triggered adaptive servo-ventilation compared with continuous positive airway pressure in patients with
chronic heart failure with coexisting obstructive sleep apnea and Cheyne-Stokes respiration. Circ Heart Fail; 3: 140-148.
355. Javaheri S. Pembrey’s dream: the time has come for a longterm trial of nocturnal supplemental nasal oxygen to treat central sleep apnea in congestive
heart failure. Chest 2003; 123: 322-325.
356. Andreas S, von zur Muhlen F, Stevens J, et al. Nocturnal oxygen and hypercapnic ventilatory response in patients with congestive heart failure. Respir
Med 1998; 92: 426-431.
357. Shigemitsu M, Nishio K, Kusuyama T, et al. Nocturnal oxygen therapy prevents progress of congestive heart failure with central sleep apnea. Int J
Cardiol 2007; 115: 354-360.
358. Toyama T, Seki R, Kasama S, et al. Effectiveness of nocturnal home oxygen therapy to improve exercise capacity, cardiac function and cardiac
sympathetic nerve activity in patients with chronic heart failure and central sleep apnea. Circ J 2009; 73: 299-304.
359. Sasayama S, Izumi T, Seino Y, et al. Effects of nocturnal oxygen therapy on outcome measures in patients with chronic heart failure and cheyne-
stokes respiration. Circ J 2006; 70: 1-7.
360. Sasayama S, Izumi T, Asanoi H, et al. Long-term benefits of nocturnal home oxygen therapy in patients with chronic heart failure and central sleep
apnea. J Card Failure 2007; 13: S44.
361. Seino Y, Imai H, Nakamoto T, et al. Clinical efficacy and cost-benefit analysis of nocturnal home oxygen therapy in patients with central sleep apnea
caused by chronic heart failure. Circ J 2007; 71: 1738-1743.
362. Pullicino PM, Halperin JL, Thompson JL. Stroke in patients with heart failure and reduced left ventricular ejection fraction. Neurology 2000; 54: 288-
294.
363. Kopecky SL, Gersh BJ, McGoon MD, et al. The natural history of lone atrial fibrillation. A population-based study over three decades. N Eng J Med
1987; 317: 669-674.
364. Sanders P, Morton JB, Davidson NC, et al. Electrical remodeling of the atria in congestive heart failure: electrophysiological and electroanatomic
mapping in humans. Circulation 2003; 108: 1461-1468.
365. Goette A, Staack T, Rocken C, et al. Increased expression of extracellular signal-regulated kinase and angiotensinconverting enzyme in human atria
during atrial fibrillation. J Am Coll Cardiol 2000; 35: 1669-1677.
366. Nakashima H, Kumagai K, Urata H, et al. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000; 101: 2612-2617.
367. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Archives
of internal medicine 1994; 154: 1449-1457.
368. Shivkumar K, Jafri SM, Gheorghiade M. Antithrombotic therapy in atrial fibrillation: a review of randomized trials with special reference to the Stroke
Prevention in Atrial Fibrillation II (SPAF II) Trial. Progress in cardiovascular diseases 1996; 38: 337-342.
369. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task
Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with
the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29:
2388-2442.
370. 日本循環器学会．心房細動治療（薬物）ガイドライン（2008年改訂版）．心房細動治療（薬物）ガイドライン（2008年改訂版）．2008.
371. 日本循環器学会．循環器疾患における抗凝固・抗血小板治療に関するガイドライン．循環器疾患における抗凝固・抗血小板治療に関するガイドライン．
372. Fuster V, Gersh BJ, Giuliani ER, et al. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 1981; 47: 525-531.
373. Dunkman WB, Johnson GR, Carson PE, et al. Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies
Group. Circulation 1993; 87 (6 Suppl.): VI94-101.
374. Massie BM, Collins JF, Ammon SE, et al. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and
Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation 2009; 119: 1616-1624.
375. Cokkinos DV, Haralabopoulos GC, Kostis JB, et al. Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. Eur J Heart Fail 2006;
8: 428-432.
376. Loh E, Sutton MS, Wun CC, et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Eng J Med 1997; 336: 251-257.
377. Dries DL, Rosenberg YD, Waclawiw MA, et al. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus
rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. J Am Coll Cardiol 1997; 29: 1074-1080.
378. Stratton JR, Nemanich JW, Johannessen KA, et al. Fate of left ventricular thrombi in patients with remote myocardial infarction or idiopathic
cardiomyopathy. Circulation 1988; 78: 1388-1393.
379. Stratton JR, Resnick AD. Increased embolic risk in patients with left ventricular thrombi. Circulation 1987; 75: 1004-1011.
380. Lip GY, Gibbs CR. Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm: a Cochrane systematic review. Qjm 2002; 95:
461-468.
381. Al-Khadra AS, Salem DN, Rand WM, et al. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD)
trial. J Am Coll Cardiol 1998; 31: 419-425.
382. Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the
Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol 1997; 79: 115-119.
383. Spaulding C, Charbonnier B, Cohen-Solal A, et al. Acute hemodynamic interaction of aspirin and ticlopidine with enalapril: results of a double-blind,
randomized comparative trial. Circulation 1998; 98: 757-765.
384. McMurray JJ, Pitt B, Latini R, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008; 1:
17-24.
385. Solomon SD, Appelbaum E, Manning WJ, et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left
ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009; 119: 530-537.
386. Rouleau JL, Pfeffer MA, Stewart DJ, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients
with heart failure: IMPRESS randomised trial. Lancet 2000; 356: 615-620.
387. Udelson JE, McGrew FA, Flores E, et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular
dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol 2007; 49: 2151-2159.
388. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Eng J Med 2007; 357: 2248-2261.
389. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind,
placebo-controlled trial. Lancet 2008; 372: 1231-1239.
390. Behling A, Rohde LE, Colombo FC, et al. Effects of 5’-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a
double-blind, placebo-controlled clinical trial. J Card Failure 2008; 14: 189-197.
391. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J 1991; 121 (3 Pt 1): 951-957.
392. 平成21年度版 高齢化の状況及び高齢社会対策の実施の状況に関する年次報告（高齢社会白書）．[cited; Available from:
http://www8.cao.go.jp/kourei/whitepaper/w-2009/gaiyou/pdf/1s1s.pdf]
393. Ogawa M, Tanaka F, Onoda T, et al. A community based epidemiological and clinical study of hospitalization of patients with congestive heart failure
in Northern Iwate, Japan. Circ J 2007; 71: 455-459.
394. Liao L, Allen LA, Whellan DJ. Economic burden of heart failure in the elderly. PharmacoEconomics 2008; 26: 447-462.
395. Stanley M. Current trends in the clinical management of an old enemy: congestive heart failure in the elderly. AACN clinical issues 1997; 8: 616-626;
quiz 49-51.
396. Okura Y, Ohno Y, Ramadan MM, et al. Characterization of outpatients with isolated diastolic dysfunction and evaluation of the burden in a Japanese
community: Sado Heart Failure Study. Circ J 2007; 71: 1013-1021.
397. Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, et al. Characteristics and outcomes of hospitalized patients with heart failure and reduced vs
preserved ejection fraction. Report From the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009; 73: 1893-1900.
398. Tresch DD, McGough MF. Heart failure with normal systolic function: a common disorder in older people. Journal of the American Geriatrics Society
1995; 43: 1035-1042.
399. 大川真一郎，上田慶二，杉浦昌，也．老年者の心疾患・弁膜症．日老医誌 1985.
400. Jurgens CY, Hoke L, Byrnes J, et al. Why do elders delay responding to heart failure symptoms? Nursing research 2009; 58: 274-282.
1827-1835.
302. Shiomi T, Guilleminault C, Stoohs R, et al. Leftward shift of the interventricular septum and pulsus paradoxus in obstructive sleep apnea syndrome.
Chest 1991; 100: 894-902.
303. Shamsuzzaman AS, Gersh BJ, Somers VK. Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA 2003; 290: 1906-1914.
304. Solin P, Bergin P, Richardson M, et al. Influence of pulmonary capillary wedge pressure on central apnea in heart failure. Circulation 1999; 99: 1574-
1579.
305. Tkacova R, Hall MJ, Liu PP, et al. Left ventricular volume in patients with heart failure and Cheyne-Stokes respiration during sleep. Am J Respir Crit
Care Med 1997; 156: 1549-1555.
306. Solin P, Kaye DM, Little PJ, et al. Impact of sleep apnea on sympathetic nervous system activity in heart failure. Chest 2003; 123: 1119-1126.
307. Spaak J, Egri ZJ, Kubo T, et al. Muscle sympathetic nerve activity during wakefulness in heart failure patients with and without sleep apnea.
Hypertension 2005; 46: 1327-1332.
308. Arzt M, Harth M, Luchner A, et al. Enhanced ventilatory response to exercise in patients with chronic heart failure and central sleep apnea. Circulation
2003; 107: 1998-2003.
309. Javaheri S. A mechanism of central sleep apnea in patients with heart failure. N Eng J Med 1999; 341: 949-954.
310. Wilcox I, McNamara SG, Dodd MJ, et al. Ventilatory control in patients with sleep apnoea and left ventricular dysfunction: comparison of obstructive
and central sleep apnoea. Eur Respir J 1998; 11: 7-13.
311. Marin JM, Carrizo SJ, Vicente E, et al. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment
with continuous positive airway pressure: an observational study. Lancet 2005; 365: 1046-1053.
312. Buchner NJ, Sanner BM, Borgel J, et al. Continuous positive airway pressure treatment of mild to moderate obstructive sleep apnea reduces
cardiovascular risk. Am J Respir Crit Care Med 2007; 176: 1274-1280.
313. Roebuck T, Solin P, Kaye DM, et al. Increased long-term mortality in heart failure due to sleep apnoea is not yet proven. Eur Respir J 2004; 23: 735-740.
314. Wang H, Parker JD, Newton GE, et al. Influence of obstructive sleep apnea on mortality in patients with heart failure. J Am Coll Cardiol 2007; 49: 1625-
1631.
315. Lanfranchi PA, Braghiroli A, Bosimini E, et al. Prognostic value of nocturnal Cheyne-Stokes respiration in chronic heart failure. Circulation 1999; 99:
1435-1440.
316. Sin DD, Logan AG, Fitzgerald FS, et al. Effects of continuous positive airway pressure on cardiovascular outcomes in heart failure patients with and
without Cheyne-Stokes respiration. Circulation 2000; 102: 61-66.
317. Javaheri S, Shukla R, Zeigler H, et al. Central sleep apnea, right ventricular dysfunction, and low diastolic blood pressure are predictors of mortality in
systolic heart failure. J Am Coll Cardiol 2007; 49: 2028-2034.
318. Corra U, Pistono M, Mezzani A, et al. Sleep and exertional periodic breathing in chronic heart failure: prognostic importance and interdependence.
Circulation 2006; 113: 44-50.
319. Hanly PJ, Zuberi-Khokhar NS. Increased mortality associated with Cheyne-Stokes respiration in patients with congestive heart failure. Am J Respir Crit
Care Med 1996; 153: 272-276.
320. Tamura A, Kawano Y, Kadota J. Carvedilol reduces the severity of central sleep apnea in chronic heart failure. Circ J 2009; 73: 295-298.
321. Javaheri S. Acetazolamide improves central sleep apnea in heart failure: a double-blind, prospective study. Am J Respir Crit Care Med 2006; 173: 234-
237.
322. Sinha AM, Skobel EC, Breithardt OA, et al. Cardiac resynchronization therapy improves central sleep apnea and Cheyne-Stokes respiration in patients
with chronic heart failure. J Am Coll Cardiol 2004; 44: 68-71.
323. Gabor JY, Newman DA, Barnard-Roberts V, et al. Improvement in Cheyne-Stokes respiration following cardiac resynchronisation therapy. Eur Respir J
2005; 26: 95-100.
324. Oldenburg O, Faber L, Vogt J, et al. Influence of cardiac resynchronisation therapy on different types of sleep disordered breathing. Eur J Heart Fail 2007;
9: 820-826.
325. Bucca CB, Brussino L, Battisti A, et al. Diuretics in obstructive sleep apnea with diastolic heart failure. Chest 2007; 132: 440-446.
326. Walsh JT, Andrews R, Starling R, et al. Effects of captopril and oxygen on sleep apnoea in patients with mild to moderate congestive cardiac failure. British
heart journal 1995; 73: 237-241.
327. Tamura A, Kawano Y, Naono S, et al. Relationship between beta-blocker treatment and the severity of central sleep apnea in chronic heart failure. Chest
2007; 131: 130-135.
328. Kara T, Novak M, Nykodym J, et al. Short-term effects of cardiac resynchronization therapy on sleep-disordered breathing in patients with systolic heart
failure. Chest 2008; 134: 87-93.
329. Somers VK, Dyken ME, Clary MP, et al. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest 1995; 96: 1897-1904.
330. Narkiewicz K, Pesek CA, van de Borne PJ, et al. Enhanced sympathetic and ventilatory responses to central chemoreflex activation in heart failure.
Circulation 1999; 100: 262-267.
331. Kaneko Y, Floras JS, Usui K, et al. Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea.
N Eng J Med 2003; 348: 1233-1241.
332. Mansfield DR, Gollogly NC, Kaye DM, et al. Controlled trial of continuous positive airway pressure in obstructive sleep apnea and heart failure. Am J Respir
Crit Care Med 2004; 169: 361-366.
333. Usui K, Bradley TD, Spaak J, et al. Inhibition of awake sympathetic nerve activity of heart failure patients with obstructive sleep apnea by nocturnal
continuous positive airway pressure. J Am Coll Cardiol 2005; 45: 2008-2011.
334. Tkacova R, Dajani HR, Rankin F, et al. Continuous positive airway pressure improves nocturnal baroreflex sensitivity of patients with heart failure and
obstructive sleep apnea. Journal of hypertension 2000; 18: 1257-1262.
335. Ryan CM, Usui K, Floras JS, et al. Effect of continuous positive airway pressure on ventricular ectopy in heart failure patients with obstructive sleep
apnoea. Thorax 2005; 60: 781-785.
336. Arias MA, Garcia-Rio F, Alonso-Fernandez A, et al. Obstructive sleep apnea syndrome affects left ventricular diastolic function: effects of nasal
continuous positive airway pressure in men. Circulation 2005; 112: 375-383.
337. Smith LA, Vennelle M, Gardner RS, et al. Auto-titrating continuous positive airway pressure therapy in patients with chronic heart failure and obstructive
sleep apnoea: a randomized placebo-controlled trial. Eur Heart J 2007; 28: 1221-1227.
338. Kasai T, Narui K, Dohi T, et al. Prognosis of patients with heart failure and obstructive sleep apnea treated with continuous positive airway pressure. Chest
2008; 133: 690-696.
339. Meurice JC, Paquereau J, Denjean A, et al. Influence of correction of flow limitation on continuous positive airway pressure efficiency in sleep
apnoea/hypopnoea syndrome. Eur Respir J 1998; 11: 1121-1127.
340. Ferguson KA, Ono T, Lowe AA, et al. A randomized crossover study of an oral appliance vs nasal-continuous positive airway pressure in the treatment of
mild-moderate obstructive sleep apnea. Chest 1996; 109: 1269-1275.
341. Naughton MT, Liu PP, Bernard DC, et al. Treatment of congestive heart failure and Cheyne-Stokes respiration during sleep by continuous positive airway
pressure. Am J Respir Crit Care Med 1995; 151: 92-97.
342. Naughton MT, Benard DC, Liu PP, et al. Effects of nasal CPAP on sympathetic activity in patients with heart failure and central sleep apnea. Am J Respir
Crit Care Med 1995; 152: 473-479.
343. Tkacova R, Liu PP, Naughton MT, et al. Effect of continuous positive airway pressure on mitral regurgitant fraction and atrial natriuretic peptide in
patients with heart failure. J Am Coll Cardiol 1997; 30: 739-745.
344. Javaheri S. Effects of continuous positive airway pressure on sleep apnea and ventricular irritability in patients with heart failure. Circulation 2000; 101:
392-397.
345. Bradley TD, Logan AG, Kimoff RJ, et al. Continuous positive airway pressure for central sleep apnea and heart failure. N Eng J Med 2005; 353: 2025-2033.
346. Arzt M, Floras JS, Logan AG, et al. Suppression of central sleep apnea by continuous positive airway pressure and transplant-free survival in heart failure:
a post hoc analysis of the Canadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failure Trial (CANPAP).
Circulation 2007; 115: 3173-3180.
347. Dohi T, Kasai T, Narui K, et al. Bi-level positive airway pressure ventilation for treating heart failure with central sleep apnea that is unresponsive to
continuous positive airway pressure. Circ J 2008; 72: 1100-1105.
348. Noda A, Izawa H, Asano H, et al. Beneficial effect of bilevel positive airway pressure on left ventricular function in ambulatory patients with idiopathic
dilated cardiomyopathy and central sleep apnea-hypopnea: a preliminary study. Chest 2007; 131: 1694-1701.
349. Johnson KG, Johnson DC. Bilevel positive airway pressure worsens central apneas during sleep. Chest 2005; 128: 2141-2150.
350. Teschler H, Dohring J, Wang YM, et al. Adaptive pressure support servo-ventilation: a novel treatment for Cheyne- Stokes respiration in heart failure.
Am J Respir Crit Care Med 2001; 164: 614-619.
351. Pepperell JC, Maskell NA, Jones DR, et al. A randomized controlled trial of adaptive ventilation for Cheyne-Stokes breathing in heart failure. Am J Respir
Crit Care Med 2003; 168: 1109-1114.
352. Philippe C, Stoica-Herman M, Drouot X, et al. Compliance with and effectiveness of adaptive servoventilation versus continuous positive airway pressure
in the treatment of Cheyne-Stokes respiration in heart failure over a six month period. Heart (British Cardiac Society) 2006; 92: 337-342.
353. Kasai T, Narui K, Dohi T, et al. First experience of using new adaptive servo-ventilation device for Cheyne-Stokes respiration with central sleep apnea
among Japanese patients with congestive heart failure: report of 4 clinical cases. Circ J 2006; 70: 1148-1154.
354. Kasai T, Usui Y, Yoshioka T, et al. Effect of flow-triggered adaptive servo-ventilation compared with continuous positive airway pressure in patients with
chronic heart failure with coexisting obstructive sleep apnea and Cheyne-Stokes respiration. Circ Heart Fail; 3: 140-148.
355. Javaheri S. Pembrey’s dream: the time has come for a longterm trial of nocturnal supplemental nasal oxygen to treat central sleep apnea in congestive
heart failure. Chest 2003; 123: 322-325.
356. Andreas S, von zur Muhlen F, Stevens J, et al. Nocturnal oxygen and hypercapnic ventilatory response in patients with congestive heart failure. Respir
Med 1998; 92: 426-431.
357. Shigemitsu M, Nishio K, Kusuyama T, et al. Nocturnal oxygen therapy prevents progress of congestive heart failure with central sleep apnea. Int J
Cardiol 2007; 115: 354-360.
358. Toyama T, Seki R, Kasama S, et al. Effectiveness of nocturnal home oxygen therapy to improve exercise capacity, cardiac function and cardiac
sympathetic nerve activity in patients with chronic heart failure and central sleep apnea. Circ J 2009; 73: 299-304.
359. Sasayama S, Izumi T, Seino Y, et al. Effects of nocturnal oxygen therapy on outcome measures in patients with chronic heart failure and cheyne-
stokes respiration. Circ J 2006; 70: 1-7.
360. Sasayama S, Izumi T, Asanoi H, et al. Long-term benefits of nocturnal home oxygen therapy in patients with chronic heart failure and central sleep
apnea. J Card Failure 2007; 13: S44.
361. Seino Y, Imai H, Nakamoto T, et al. Clinical efficacy and cost-benefit analysis of nocturnal home oxygen therapy in patients with central sleep apnea
caused by chronic heart failure. Circ J 2007; 71: 1738-1743.
362. Pullicino PM, Halperin JL, Thompson JL. Stroke in patients with heart failure and reduced left ventricular ejection fraction. Neurology 2000; 54: 288-
294.
363. Kopecky SL, Gersh BJ, McGoon MD, et al. The natural history of lone atrial fibrillation. A population-based study over three decades. N Eng J Med
1987; 317: 669-674.
364. Sanders P, Morton JB, Davidson NC, et al. Electrical remodeling of the atria in congestive heart failure: electrophysiological and electroanatomic
mapping in humans. Circulation 2003; 108: 1461-1468.
365. Goette A, Staack T, Rocken C, et al. Increased expression of extracellular signal-regulated kinase and angiotensinconverting enzyme in human atria
during atrial fibrillation. J Am Coll Cardiol 2000; 35: 1669-1677.
366. Nakashima H, Kumagai K, Urata H, et al. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000; 101: 2612-2617.
367. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Archives
of internal medicine 1994; 154: 1449-1457.
368. Shivkumar K, Jafri SM, Gheorghiade M. Antithrombotic therapy in atrial fibrillation: a review of randomized trials with special reference to the Stroke
Prevention in Atrial Fibrillation II (SPAF II) Trial. Progress in cardiovascular diseases 1996; 38: 337-342.
369. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task
Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with
the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29:
2388-2442.
370. 日本循環器学会．心房細動治療（薬物）ガイドライン（2008年改訂版）．心房細動治療（薬物）ガイドライン（2008年改訂版）．2008.
371. 日本循環器学会．循環器疾患における抗凝固・抗血小板治療に関するガイドライン．循環器疾患における抗凝固・抗血小板治療に関するガイドライン．
372. Fuster V, Gersh BJ, Giuliani ER, et al. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 1981; 47: 525-531.
373. Dunkman WB, Johnson GR, Carson PE, et al. Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies
Group. Circulation 1993; 87 (6 Suppl.): VI94-101.
374. Massie BM, Collins JF, Ammon SE, et al. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and
Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation 2009; 119: 1616-1624.
375. Cokkinos DV, Haralabopoulos GC, Kostis JB, et al. Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. Eur J Heart Fail 2006;
8: 428-432.
376. Loh E, Sutton MS, Wun CC, et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Eng J Med 1997; 336: 251-257.
377. Dries DL, Rosenberg YD, Waclawiw MA, et al. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus
rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. J Am Coll Cardiol 1997; 29: 1074-1080.
378. Stratton JR, Nemanich JW, Johannessen KA, et al. Fate of left ventricular thrombi in patients with remote myocardial infarction or idiopathic
cardiomyopathy. Circulation 1988; 78: 1388-1393.
379. Stratton JR, Resnick AD. Increased embolic risk in patients with left ventricular thrombi. Circulation 1987; 75: 1004-1011.
380. Lip GY, Gibbs CR. Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm: a Cochrane systematic review. Qjm 2002; 95:
461-468.
381. Al-Khadra AS, Salem DN, Rand WM, et al. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD)
trial. J Am Coll Cardiol 1998; 31: 419-425.
382. Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the
Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol 1997; 79: 115-119.
383. Spaulding C, Charbonnier B, Cohen-Solal A, et al. Acute hemodynamic interaction of aspirin and ticlopidine with enalapril: results of a double-blind,
randomized comparative trial. Circulation 1998; 98: 757-765.
384. McMurray JJ, Pitt B, Latini R, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008; 1:
17-24.
385. Solomon SD, Appelbaum E, Manning WJ, et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left
ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009; 119: 530-537.
386. Rouleau JL, Pfeffer MA, Stewart DJ, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients
with heart failure: IMPRESS randomised trial. Lancet 2000; 356: 615-620.
387. Udelson JE, McGrew FA, Flores E, et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular
dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol 2007; 49: 2151-2159.
388. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Eng J Med 2007; 357: 2248-2261.
389. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind,
placebo-controlled trial. Lancet 2008; 372: 1231-1239.
390. Behling A, Rohde LE, Colombo FC, et al. Effects of 5’-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a
double-blind, placebo-controlled clinical trial. J Card Failure 2008; 14: 189-197.
391. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J 1991; 121 (3 Pt 1): 951-957.
392. 平成21年度版 高齢化の状況及び高齢社会対策の実施の状況に関する年次報告（高齢社会白書）．[cited; Available from:
http://www8.cao.go.jp/kourei/whitepaper/w-2009/gaiyou/pdf/1s1s.pdf]
393. Ogawa M, Tanaka F, Onoda T, et al. A community based epidemiological and clinical study of hospitalization of patients with congestive heart failure
in Northern Iwate, Japan. Circ J 2007; 71: 455-459.
394. Liao L, Allen LA, Whellan DJ. Economic burden of heart failure in the elderly. PharmacoEconomics 2008; 26: 447-462.
395. Stanley M. Current trends in the clinical management of an old enemy: congestive heart failure in the elderly. AACN clinical issues 1997; 8: 616-626;
quiz 49-51.
396. Okura Y, Ohno Y, Ramadan MM, et al. Characterization of outpatients with isolated diastolic dysfunction and evaluation of the burden in a Japanese
community: Sado Heart Failure Study. Circ J 2007; 71: 1013-1021.
397. Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, et al. Characteristics and outcomes of hospitalized patients with heart failure and reduced vs
preserved ejection fraction. Report From the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009; 73: 1893-1900.
398. Tresch DD, McGough MF. Heart failure with normal systolic function: a common disorder in older people. Journal of the American Geriatrics Society
1995; 43: 1035-1042.
399. 大川真一郎，上田慶二，杉浦昌，也．老年者の心疾患・弁膜症．日老医誌 1985.
400. Jurgens CY, Hoke L, Byrnes J, et al. Why do elders delay responding to heart failure symptoms? Nursing research 2009; 58: 274-282.
文献
慢性心不全治療ガイドライン（2010年改訂版）
Guidelines for Treatment of Chronic Heart Failure（JCS 2010）
Guidelines for Treatment of Chronic Heart Failure（JCS 2010）